S. Korea’s Daewoong, Dong A, Yuhan, Others Brace For U.S. FTA Impact
This article was originally published in PharmAsia News
Executive Summary
South Korea’s pharmaceutical industry is bracing for more competition and lower prices for its products as a free-trade agreement with the U.S. becomes operable March 15, triggering the April 1 changes.